{"product_id":"akebia-pestle-analysis","title":"Akebia PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSpot the external forces shaping Akebia’s prospects—from regulatory scrutiny and biotech funding cycles to shifting healthcare policies and tech-driven R\u0026amp;D advances—and turn those signals into strategy; purchase the full PESTLE for a ready-made, editable deep dive that speeds your analysis and strengthens investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare reimbursement policy changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act's drug pricing provisions continue to pressure Medicare Part D, with estimated manufacturer rebates and price negotiations projected to reduce net drug revenues by up to 10–15% for some specialty drugs through 2026; for Akebia this heightens pricing scrutiny for Vafseo. Changes to the ESRD bundled payment—affecting roughly 550,000 US dialysis patients—alter incentives for adopting add-on therapies, impacting potential uptake of HIF-PHI treatments. Navigating federal reimbursement, including QIP and ESRD Prospective Payment System adjustments, is critical to secure formulary placement and preserve net present value of Vafseo revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA regulatory oversight and scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe FDA maintains stringent oversight of anemia treatments after safety concerns in the HIF-PHI class, with 2024 adverse-event reviews increasing review times by ~20% industry-wide; Akebia must sustain transparent FDA engagement to meet post-marketing requirements and potential label expansions tied to verifiable safety data. Political pressure to balance innovation and patient safety affects approval timelines and costs—median oncology\/rare-disease approval costs rose to $300–400M in 2023–24—raising capital needs for Akebia’s pipeline. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade and geopolitical stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Akebia scales via partnerships in Japan (Kyowa Kirin licensing) and Europe, shifts in tariffs or sanctions could disrupt APIs and finished-product flows; Japan and EU accounted for roughly 30% of ex-US royalties in 2024, exposing revenue to trade risk.\u003c\/p\u003e\n\u003cp\u003eGeopolitical tensions—e.g., 2024 supply-chain reallocations after China export controls—raise procurement costs; a 5-10% tariff swing on APIs could increase COGS materially for small-mid biotech players like Akebia.\u003c\/p\u003e\n\u003cp\u003eActive monitoring of trade policy, customs regimes and diplomatic ties is essential to protect royalty streams and maintain access to contract manufacturing and clinical supply chains across key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal funding for kidney disease research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal prioritization like the 2019 Advancing American Kidney Health initiative and expanded FY2025 NIH kidney funding (~$575M projected for kidney research in 2024–25) increases screening and early CKD detection, enlarging the treatable patient base and boosting demand for novel therapeutics.\u003c\/p\u003e\n\u003cp\u003eHigher federal support and incentives for home dialysis align with Akebia’s portfolio and could accelerate uptake of partner therapies and supportive care solutions, improving market access and reimbursement prospects.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvancing American Kidney Health drives screening\/early detection, expanding patient pool\u003c\/li\u003e\n\u003cli\u003eNIH\/kidney funding ~ $575M (2024–25) supports R\u0026amp;D pipeline growth\u003c\/li\u003e\n\u003cli\u003ePolicy emphasis on home dialysis favors Akebia’s market positioning and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reform and drug pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing proposals to cap seniors' out-of-pocket costs (e.g., Medicare cap bills targeting $2,000–$2,500\/year) could increase patient access to Akebia’s anemia and nephrology therapies, potentially expanding addressable market by millions of beneficiaries; CMS drug spending reached $131B in 2024, highlighting fiscal pressure on pricing.\u003c\/p\u003e\n\u003cp\u003eRebate reform and PBM transparency debates—Congressional proposals in 2024 aimed at eliminating certain rebates—could raise net realized prices for Akebia or compress commercial margins depending on passthrough mechanics and contracting.\u003c\/p\u003e\n\u003cp\u003eMonitoring legislative timelines and modeling scenarios is critical: a 10–20% shift in net price realization would materially affect 2025–2027 revenue forecasts and valuation models.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePotential Medicare OOP cap: $2,000–$2,500\/year\u003c\/li\u003e\n\u003cli\u003eCMS drug spending: $131B (2024)\u003c\/li\u003e\n\u003cli\u003eRebate reform could change net prices by ~10–20%\u003c\/li\u003e\n\u003cli\u003eEssential to update revenue forecasts with legislative scenarios\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy, funding, and FDA delays squeeze Vafseo pricing and market opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIRAs drug pricing, ESRD bundle changes, and potential Medicare OOP caps (proposed $2,000–$2,500) pressure Vafseo pricing and uptake; NIH kidney funding (~$575M 2024–25) and home-dialysis incentives expand addressable market; FDA safety scrutiny and longer review times (~+20% in 2024) raise approval costs; trade\/tariff risks (5–10% API cost swing) threaten COGS and ex-US royalties (~30% of 2024 ex-US royalties).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare spend\u003c\/td\u003e\n\u003ctd\u003e$131B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH kidney funding\u003c\/td\u003e\n\u003ctd\u003e$575M (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review delay\u003c\/td\u003e\n\u003ctd\u003e+20% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI tariff risk\u003c\/td\u003e\n\u003ctd\u003e5–10% COGS swing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Akebia across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends, industry-specific examples, forward-looking insights, and practical implications to help executives, consultants, and investors identify risks, opportunities, and strategy actions for market and regulatory scenarios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise PESTLE summary tailored to Akebia that highlights regulatory, market, and technological risks for quick inclusion in presentations or strategy sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-benefit analysis of HIF-PHI vs ESAs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVafseo’s uptake hinges on drug-cost parity with ESAs; 2024 U.S. Medicare Part B reimbursement for injectable ESAs averages about $1,200–$1,800 per patient\/month in dialysis settings, so Akebia must price oral HIF-PHI to match or undercut total per-patient costs.\u003c\/p\u003e\n\u003cp\u003eDialysis centers factor administration savings—oral dosing avoids roughly $150–$300 monthly nursing\/infusion costs—and lower monitoring could cut overall cost of care by an estimated 5–15% versus injectables.\u003c\/p\u003e\n\u003cp\u003eTo secure share in a cost-sensitive market, Akebia needs real-world pharmacoeconomic data showing Vafseo achieves equal efficacy with net healthcare savings; payers in 2024 increasingly demand value-based contracting and outcomes data. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on R\u0026amp;D and manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising costs for lab materials, specialized labor, and clinical trials have pushed biopharma input prices up ~8–12% in 2024, straining Akebia’s cash runway after 2023 net loss of $156M; controlling these inflationary expenses is critical to restore a path toward sustained profitability. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrevailing US federal funds rate at 5.25–5.50% (Dec 2025 target range) raises Akebia’s borrowing costs, increasing interest expense on new debt and potentially reducing available financing for R\u0026amp;D and commercialization.\u003c\/p\u003e\n\u003cp\u003eHigher rates compress valuations by discounting future cash flows, which could lower Akebia’s market cap from 2024–2025 revenue expectations (2025 consensus revenue ~$160–180M among analysts).\u003c\/p\u003e\n\u003cp\u003eVolatile capital markets in 2024–2025 saw biotech IPO and secondary issuance activity decline ~40% year-over-year, so Akebia must preserve liquidity and flexible debt covenants to support commercial scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprevenue from international partnerships exposes akebia to currency risk notably jpy and eur movements that can alter reported royalty milestone income in a depreciation vs usd reduced euro-denominated revenues by an estimated for similar biotech peers.\u003e\u003cpimplementing hedges or diversifying geographic revenue can stabilize results akebia-like firms that hedged in cut fx volatility by\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJPY and EUR swings materially affect reported royalties\u003c\/li\u003e\n\u003cli\u003e5% currency moves can change revenues by several million USD\u003c\/li\u003e\n\u003cli\u003eHedging reduced FX volatility ~40% for peers in 2023\u003c\/li\u003e\n\u003cli\u003eGeographic revenue diversification mitigates single-currency risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pimplementing\u003e\u003c\/prevenue\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket penetration in the dialysis sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe economic health of major dialysis providers like Fresenius and DaVita, which together serve over 70% of US dialysis patients, directly affects Akebia’s sales and pricing power; Fresenius and DaVita reported combined 2024 dialysis revenues exceeding $30 billion.\u003c\/p\u003e\n\u003cp\u003eOngoing consolidation has increased buyer leverage, enabling larger rebates—DaVita negotiated estimated formulary discounts up to 20% in recent contracts—pressuring Akebia’s margins.\u003c\/p\u003e\n\u003cp\u003eTherefore, Akebia must analyze providers’ capex, patient growth (~2% annual), and payer mixes to secure formulary placement and favorable protocol inclusion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMajor providers control \u0026gt;70% market share\u003c\/li\u003e\n\u003cli\u003eCombined dialysis revenue \u0026gt;$30B (2024)\u003c\/li\u003e\n\u003cli\u003eContract rebates\/discounts up to ~20%\u003c\/li\u003e\n\u003cli\u003ePatient growth ≈2% annually\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral ESA cuts $150–300\/mo, may trim care 5–15% as costs, rates, rebates pressure Akebia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVafseo pricing must match injectable ESA total costs (~$1,200–$1,800\/month dialysis); oral dosing saves ~$150–$300\/month in admin and may cut care costs 5–15%. Inflation raised biopharma input costs ~8–12% in 2024, aggravating Akebia’s post-2023 $156M net loss; 2024–25 revenue consensus ~$160–180M. Higher rates (Fed 5.25–5.50%) raise borrowing costs; FX moves (5% EUR) can swing revenues $3–5M; major providers (\u0026gt;70% share) drive rebates up to ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eESA cost (dialysis)\u003c\/td\u003e\n\u003ctd\u003e$1,200–$1,800\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin savings (oral)\u003c\/td\u003e\n\u003ctd\u003e$150–$300\/mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost inflation\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAkebia 2023 net loss\u003c\/td\u003e\n\u003ctd\u003e$156M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue consensus\u003c\/td\u003e\n\u003ctd\u003e$160–$180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX sensitivity (5% EUR)\u003c\/td\u003e\n\u003ctd\u003e$3–$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis provider market share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical rebates\u003c\/td\u003e\n\u003ctd\u003eup to ~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAkebia PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Akebia PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751792062841,"sku":"akebia-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/akebia-pestle-analysis.png?v=1772234732","url":"https:\/\/matrixbcg.com\/products\/akebia-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}